Got this in an email to day...
Wednesday, 19 June 2024CSL - CSL LIMITED
Macquarie rates CSL as Outperform (1) - Macquarie assumes approval for CSL competitor Argenx's Vyvgart Hytrulo (FcRn antagonist) in the treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). The US FDA has set a PDUFA target action date of June 21 for the product.
The broker estimates FcRn antagonists could reduce Immunoglobulin (Ig) use by -2% per annum, though assumes around 75% of volume displaced by FcRn antagonists will be redeployed into other indications/geographies.
The Outperform rating and $330.00 target are retained for CSL.
Target price is $330.00 Current Price is $293.87 Difference: $36.13 If CSL meets the Macquarie target it will return approximately 12% (excluding dividends, fees and charges). Current consensus price target is $316.73, suggesting upside of 7.8%(ex-dividends)The company's fiscal year ends in June.
Forecast for FY24:
Macquarie forecasts a full year FY24 dividend of 414.70 cents and EPS of 928.50 cents . At the last closing share price the estimated dividend yield is 1.41%. At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 31.65. How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 924.3, implying annual growth of N/A. Current consensus DPS estimate is 401.9, implying a prospective dividend yield of 1.4%. Current consensus EPS estimate suggests the PER is 31.8.
Forecast for FY25:
Macquarie forecasts a full year FY25 dividend of 509.22 cents and EPS of 1099.25 cents . At the last closing share price the estimated dividend yield is 1.73%. At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 26.73. How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 1164.6, implying annual growth of 26.0%. Current consensus DPS estimate is 512.9, implying a prospective dividend yield of 1.7%. Current consensus EPS estimate suggests the PER is 25.2.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.Market Sentiment: 0.8All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
- Forums
- ASX - By Stock
- CSL
- CSL - $300 and beyond
CSL - $300 and beyond, page-87
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
|
|||||
Last
$303.10 |
Change
-0.890(0.29%) |
Mkt cap ! $146.3B |
Open | High | Low | Value | Volume |
$304.30 | $304.97 | $300.85 | $224.2M | 740.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3955 | $302.81 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$303.14 | 535 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3955 | 302.810 |
1 | 17 | 302.600 |
1 | 2016 | 302.510 |
1 | 905 | 302.050 |
1 | 250 | 301.650 |
Price($) | Vol. | No. |
---|---|---|
303.140 | 535 | 1 |
303.150 | 400 | 2 |
303.250 | 555 | 2 |
303.340 | 906 | 1 |
303.430 | 1084 | 1 |
Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |